Design consideration for long-acting antagonists.
D000179:Acrylates; D001702:Biopharmaceutics; D003496:Cyclazocine / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004578:Electron Spin Resonance Spectroscopy; D006207:Half-Life; D006241:Haptens; D006801:Humans; D007700:Kinetics; D009292:Narcotic Antagonists / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D011863:Radioimmunoassay; D013113:Spin Labels; D019966:Substance-Related Disorders / Q000188:drug therapy*; D013997:Time Factors
D000179:Acrylates; D003692:Delayed-Action Preparations; D006241:Haptens; D009292:Narcotic Antagonists; D013113:Spin Labels; D003496:Cyclazocine